Successful treatment of severe refractory idiopathic thrombocytopenic purpura with liposomal doxorubicin.
Idiopathic thrombocytopenic purpura (ITP) is refractory to initial treatment (steroids and splenectomy) in 25 to 30% of patients. These patients have a significant risk of fatal hemorrhage. Two patients with ITP refractory to multiple interventions and severe depression of platelet counts responded to treatment with liposomal doxorubicin with a return of platelet counts to normal. The drug is easily administered and was well tolerated. Use of this drug in refractory ITP merits further study.
Cosgriff
T M
TM
Hematology-Oncology Services, New Orleans, Louisiana 70006, USA.
Black
M L
ML
Stein
W
W
D000328:Adult; D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage*; D004317:Doxorubicin / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D008081:Liposomes; D008297:Male; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000188:drug therapy*
D000903:Antibiotics, Antineoplastic; D008081:Liposomes; D004317:Doxorubicin